Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Rheumatoid Arthritis Drugs Market Worth $30.4 Billion by 2025: Grand View Research, Inc.

This image opens in the lightbox

News provided by

Grand View Research, Inc.

19 Feb, 2018, 11:15 GMT

Share this article

Share toX

Share this article

Share toX

SAN FRANCISCO, February 19, 2018 /PRNewswire/ --

The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.

Browse full research report with TOC on "Rheumatoid Arthritis Drugs/Therapeutics Market Size Analysis Report By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC), And Segment Forecasts, 2014 - 2025" at: https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market

Further Key Findings From the Report Suggest: 

  • North America held 56.6% of the market in 2016 due to rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment
  • Due to growing popularity, the biopharmaceuticals segment is projected to exhibit a CAGR of 8.3% during the forecast period
  • Prescriptions are anticipated to emerge as more reliable and a preferred sales channel over the same period
  • Asia Pacific is the most promising region, registering a CAGR of 9.5% between 2017 and 2025
  • Some of the key players in rheumatoid arthritis market are AbbVie; Boehringer Ingelheim GmbH; Novartis AG; Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; UCB S.A.; Johnson & Johnson Services, Inc.; and Amgen, Inc.

Browse related reports by Grand View Research: 

  • Kidney Cancer Drugs Market - The Global kidney cancer drugs market is expected to grow at an estimated CAGR of 17% over the forecast period. Renal cell carcinoma (RCC) is the most common form of cancer found in the kidney.
  • Anxiety Disorders And Depression Treatment Market - The global anxiety disorders and depression treatment market size was valued at USD 15.2 billion in 2015 and is anticipated to show steady growth due to the increasing prevalence of anxiety disorder and depression worldwide.
  • Blood Preparation Market - The global blood preparation market was valued at USD 42.49 billion in 2014 and is expected to grow at a CAGR of 4.2% over the forecast period.
  • Hemoglobinopathies Market - The global hemoglobinopathies market size was valued at USD 4.2 billion in 2014.

Grand View Research has segmented the rheumatoid arthritis drugs/therapeutics market on the basis of molecule types, sales channels, and region: 

  • Rheumatoid Arthritis Therapeutics Molecule Outlook (Revenue, USD Million, 2014 - 2025) 
    • Pharmaceuticals
      • NSAIDs
      • Analgesics
      • DMARDs
      • Glucocorticoids
    • Biopharmaceuticals
      • Biologics
        • TNF-α antagonists
        • T-cell inhibitors
        • CD20 antigen
        • JAK inhibitors
        • anti-IL6 biologics
      • Biosimilars
        • CD20 antigen
        • TNF-α antagonists
  • Rheumatoid Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2014 - 2025) 
    • Prescription
    • Over-the-Counter (OTC)
  • Rheumatoid Arthritis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
    • Asia Pacific
      • Japan
      • China
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Read Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Modal title

Also from this source

Vineet Agarwal Joins Grand View Research as Investor and Board Member

Vineet Agarwal Joins Grand View Research as Investor and Board Member

We are pleased to announce that Vineet Agarwal, a seasoned business leader and investor with over 20 years of experience in strategy, research &...

Grand View Research's Latest Market Research Findings Predict Major Shifts in Flooring Market by 2030

Grand View Research's Latest Market Research Findings Predict Major Shifts in Flooring Market by 2030

The global flooring market size is estimated to reach USD 534.6 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.